Definition of ubiquitination modulator COP1 as a novel therapeutic target in human hepatocellular carcinoma

Cancer Research

Volumn 70, Issue 21, 2010, Pages 8264-8269

  Lee, Yun Han ^a   Andersen, Jesper B ^a   Song, Ho Taek ^b,d   Judge, Adam D ^c   Seo, Daekwan ^a   Ishikawa, Tsuyoshi ^a   Marquardt, Jens U ^a   Kitade, Mitsuteru ^a   Durkin, Marian E ^a   Raggi, Chiara ^a   Woo, Hyun Goo ^a,e   Conner, Elizabeth A ^a   Avital, Itzhak ^a   MacLachlan, Ian ^c   Factor, Valentina M ^a   Thorgeirsson, Snorri S ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c Tekmira Pharmaceuticals Corporation   (Canada)

^d Yonsei University College of Medicine   (South Korea)

^e Ajou University School of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG CARRIER; LIPID; NUCLEIC ACID; PROTEIN P53; SMALL INTERFERING RNA; STABLE NUCLEIC ACID LIPID PARTICLE; UBIQUITIN PROTEIN LIGASE COP1; UBIQUITIN PROTEIN LIGASE COP1 1; UBIQUITIN PROTEIN LIGASE COP1 2; UBIQUITIN PROTEIN LIGASE COP1 3; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CELL PROLIFERATION; CELL STRAIN HEPG2; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG TARGETING; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; GENE SILENCING; GENE TARGETING; GROWTH INHIBITION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMMUNE RESPONSE; LIVER CELL CARCINOMA; MICROARRAY ANALYSIS; MOUSE; MUTANT; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR XENOGRAFT; UBIQUITINATION;

ANIMALS; BLOTTING, WESTERN; CARCINOMA, HEPATOCELLULAR; CELL CYCLE; GENE EXPRESSION PROFILING; HUMANS; LIVER NEOPLASMS; MALE; MICE; MICE, SCID; MUTATION; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53; UBIQUITIN; UBIQUITIN-PROTEIN LIGASES; UBIQUITINATION;

EID: 78449283414     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-10-0749     Document Type: Article

References (18)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics. CA Cancer J Clin 2005;55:74-108.
2. Llovet JM, Bruix J. Molecular targeted therapies in hepatocellular carcinoma. Hepatology 2008;48:1312-27.
3. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology 2005;42:1208-36.
4. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-90.
5. Farazi PA, DePinho RA. Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer 2006;6:674-87.
6. Thorgeirsson SS, Grisham JW. Molecular pathogenesis of human hepatocellular carcinoma. Nat Genet 2002;31:339-46.
7. Feitelson MA, Sun B, Satiroglu Tufan NL, et al. Genetic mechanisms of hepatocarcinogenesis. Oncogene 2002;21:2593-604.
8. Roberts LR, Gores GJ. Hepatocellular carcinoma: molecular pathways and new therapeutic targets. Semin Liver Dis 2005;25:212-25.
9. Lee JS, Chu IS, Heo J, et al. Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling. Hepatology 2004;40:667-76.
10. Kato JY, Yoneda-Kato N. Mammalian COP9 signalosome. Genes Cells 2009;14:1209-25.
11. Dornan D, Wertz I, Shimizu H, et al. The ubiquitin ligase COP1 is a critical negative regulator of p53. Nature 2004;429:86-92.
12. Morrissey DV, Lockridge JA, Shaw L, et al. Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs. Nat Biotechnol 2005;23:1002-7.
13. Zimmermann TS, Lee AC, Akinc A, et al. RNAi-mediated gene silencing in non-human primates. Nature 2006;441:111-4.
14. Judge AD, Robbins M, Tavakoli I, et al. Confirming the RNAi-mediated mechanism of action of siRNA-based cancer therapeutics in mice. J Clin Invest 2009;119:661-73.
15. Hsu IC, Tokiwa W, Bennett RA, et al. p53 gene mutation and integrated hepatitis B viral DNA sequences in human liver cancer cell lines. Carcinogenesis 1993;14:987-92.
16. Weisz L, Oren M, Rotter V. Transcription regulation by mutant p53. Oncogene 2007;26:2202-11.
17. Li L, Fattah EA, Cao G, et al. Glioma pathogenesis-related protein 1 exerts tumor suppressor activities through proapoptotic reactive oxygen species-cJun-NH2 kinase signaling. Cancer Res 2008;68:434-43.
18. Judge AD, Bola G, Lee AC, MacLachlan I. Design of noninflammatory synthetic siRNA mediating potent gene silencing in vivo. Mol Ther 2005;13:494-504.